Clinical Trials Logo

Mucopolysaccharidosis VI clinical trials

View clinical trials related to Mucopolysaccharidosis VI.

Filter by:

NCT ID: NCT00104234 Completed - Clinical trials for Mucopolysaccharidosis VI

Study of rhASB in Patients With Mucopolysaccharidosis VI

Start date: February 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.

NCT ID: NCT00067470 Completed - Clinical trials for Mucopolysaccharidosis VI

Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the ability of rhASB versus placebo to enhance endurance in patients with Mucopolysaccharidosis VI (MPS VI), as evidenced by an increase in the number of meters walked in the 12 minute walk test at Week 24 compared with baseline.

NCT ID: NCT00048711 Completed - Clinical trials for Mucopolysaccharidosis VI

Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI

Start date: March 2002
Phase: Phase 2
Study type: Interventional

The purpose of the study is evaluate the efficacy, safety, and pharmacokinetics of weekly intravenous infusions of 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) in patients diagnosed with Mucopolysaccharidosis VI (MPS VI)

NCT ID: NCT00048620 Completed - Clinical trials for Mucopolysaccharidosis VI

Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Start date: September 2000
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.